Anaplastic thyroid carcinoma, or ATC, is rare but exceptionally aggressive. Unlike many differentiated thyroid cancers, ATC can grow rapidly, invade nearby structures, and spread before treatment has had time to take effect. The BRAF V600E mutation is one of the most important genetic alterations in a subset of these tumors. It changes the BRAF protein so that it remains abnormally active, driving the MAPK signaling pathway, a molecular chain that regulates proliferation, survival, and cellular behavior. Dabrafenib is designed to inhibit mutant BRAF, cutting off this signal at a critical point. Yet cancer cells are not passive targets. Under therapeutic pressure, they can adapt, rewire signaling networks, and alter the way they process nutrients.

The central insight of the new work is that drug resistance is not solely a matter of changing receptors or acquiring additional mutations. It can also involve a shift in the cell’s internal economy. Cancer cells require a continuous supply of ATP for energy, reducing equivalents to control chemical reactions, and carbon-based molecules for constructing DNA, proteins, membranes, and other cellular components. Glucose is a major source of these materials, but its carbon can be redirected into multiple biochemical pathways. PHGDH sits at the entrance to one such branch: the serine synthesis pathway. It diverts the glycolytic intermediate 3-phosphoglycerate away from energy production and toward the generation of serine and related metabolites.

Serine is more than a simple amino acid. It contributes to the production of glycine, nucleotides, phospholipids, and glutathione, an important antioxidant system. Through these connections, the serine synthesis pathway can influence how cells replicate their genomes, build new membranes, and withstand oxidative stress. PHGDH also participates in the cell’s management of redox balance, helping shape the availability of molecules required for maintaining chemical stability during rapid growth. In tumors exposed to a BRAF inhibitor, these functions may become particularly valuable. If dabrafenib suppresses the signaling program that normally supports proliferation, a resistant cell may compensate by strengthening metabolic pathways that preserve survival and biosynthetic capacity.

Kim and You’s study identifies PHGDH inhibition as a means of disrupting that compensation. The reported effect is described as metabolic rewiring: rather than simply adding another brake to the same signaling pathway, PHGDH inhibition changes the flow of nutrients through the cancer cell. This distinction matters because resistant tumors often survive by routing around a blocked pathway. A second drug that targets the same route may have limited impact if the cancer has already activated a parallel mechanism. By interfering with serine-related metabolism, however, PHGDH inhibition may remove the raw materials or redox support that resistant BRAF-mutant cells require to remain viable under dabrafenib treatment.

The approach also illustrates why combination therapies are increasingly being designed around the relationship between signaling and metabolism. Oncogenic BRAF signaling can alter glucose uptake, mitochondrial activity, amino-acid use, and the expression of metabolic enzymes. At the same time, metabolic changes can feed back into signaling by modifying the cellular energy state and the chemical environment in which proteins operate. A tumor treated with dabrafenib may therefore not be understood as a static collection of mutated cells. It is a dynamic system responding to stress. The combination of BRAF blockade and PHGDH inhibition aims to attack both the growth command and the adaptive fuel network that can help cancer cells survive its suppression.

From a technical perspective, the strategy may produce several layers of stress at once. Restricting PHGDH activity can reduce the ability of cells to generate serine through glucose-derived intermediates. That shortage may affect nucleotide synthesis, limiting the materials needed for DNA replication and repair. It may also weaken phospholipid production, which is essential for expanding cellular membranes during division. At the same time, reduced support for glutathione production could leave tumor cells more exposed to reactive oxygen species. These chemically reactive molecules arise naturally during metabolism and can increase when cells are under therapeutic pressure. A cancer cell that can no longer buffer oxidative damage may cross a threshold leading to growth arrest or cell death.

The findings are especially notable because dabrafenib resistance remains a major obstacle even when a tumor carries a mutation that appears directly druggable. Targeted therapies can produce striking responses, but those responses may be temporary. Some resistant cells reactivate MAPK signaling through alterations elsewhere in the pathway, while others engage receptor tyrosine kinases, change cell identity, or enter a slower-growing state that tolerates treatment. Metabolic rewiring adds another dimension to this problem. It suggests that the cells surviving therapy may not merely be genetically different; they may also be physiologically different, using nutrients in a way that makes them less dependent on the pathway originally targeted.

The study’s implications extend beyond thyroid cancer, although its immediate focus is BRAF V600E anaplastic thyroid carcinoma. PHGDH is overexpressed or relied upon in several cancer contexts, and the serine synthesis pathway has attracted attention as a potential therapeutic target. Still, an experimental result in a cancer model does not automatically establish a safe or effective treatment for patients. Serine metabolism is also important in normal tissues, and the therapeutic challenge will be to determine whether PHGDH can be inhibited strongly enough to affect resistant tumor cells without causing unacceptable toxicity. Future work will need to clarify which tumors are most dependent on PHGDH, identify biomarkers that predict response, and establish the appropriate dose, timing, and sequence for combining a PHGDH inhibitor with dabrafenib.

The broader message is that cancer resistance may be defeated by targeting not only what tumors signal, but also how they survive. In BRAF V600E anaplastic thyroid carcinoma, the work by Kim and You positions PHGDH as a metabolic pressure point that becomes important when dabrafenib pushes cancer cells into an adaptive state. If these findings are confirmed in additional models and ultimately in clinical studies, the combination could help convert a resistant tumor’s survival strategy into a liability. The research offers a vivid example of modern oncology’s expanding battlefield: the fight is no longer confined to mutated genes and signaling proteins, but includes the intricate metabolic networks that keep malignant cells alive.

Subject of Research: PHGDH inhibition and metabolic rewiring as a strategy to overcome dabrafenib resistance in BRAF V600E anaplastic thyroid carcinoma.

Article Title: PHGDH inhibition overcomes dabrafenib resistance through metabolic rewiring in BRAF V600E anaplastic thyroid carcinoma.

Article References: Kim, S.Y., You, MH. “PHGDH inhibition overcomes dabrafenib resistance through metabolic rewiring in BRAF V600E anaplastic thyroid carcinoma.” Cell Death Discovery (2026). https://doi.org/10.1038/s41420-026-03293-7

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03293-7

Keywords: PHGDH, dabrafenib resistance, metabolic rewiring, BRAF V600E, anaplastic thyroid carcinoma, serine synthesis pathway, targeted therapy, cancer metabolism

Central to the pathobiology of ATC are critical disruptions in intracellular signaling networks that drive malignant transformation, proliferation, and invasive potential. The mitogen-activated protein kinase (MAPK) pathway and the phosphoinositide 3-kinase (PI3K)-AKT-mammalian target of rapamycin (mTOR) pathway emerge as pivotal conduits of oncogenic signaling. Aberrations in these cascades foster a cellular milieu conducive to unchecked growth and resistance to apoptosis, delineating them as prime molecular targets. Mutations in pivotal oncogenes and tumor suppressors such as BRAF, RAS, PIK3CA, TP53, and TERT delineate distinct genetic landscapes within ATC, illuminating potential avenues for subclassification and personalized medicine approaches.

Genomic characterization has unveiled the prevalence of the BRAF V600E mutation, which hyperactivates the MAPK pathway, serving as a cornerstone for the advent of targeted inhibitors. The deployment of BRAF inhibitors, in conjunction with MEK inhibitors, exemplifies a dual-target blockade strategy that has demonstrated encouraging results, including tumor size reduction sufficient to facilitate surgical resection. This combinational therapy approach signifies a paradigm shift from conventional trimodal treatments, which, despite encompassing surgery, chemotherapy, and radiation, often fall short in managing advanced ATC stages due to intrinsic therapeutic resistance and pervasive tumor heterogeneity.

Immunotherapeutic strategies are rapidly gaining traction as adjunctive treatments, predicated on the molecular and cellular composition of the ATC tumor microenvironment. A hallmark of ATC is the abundant infiltration of immune cells and upregulated programmed death-ligand 1 (PD-L1), phenomena that provide a rationale for employing immune checkpoint inhibitors targeting PD-1/PD-L1 axes. Despite these promising biological rationales, clinical responses have been heterogeneous, underscoring the imperative for intensified research to discern biomarkers predictive of response and to refine combinatorial immunotherapy regimens for improved efficacy.

On the diagnostic frontier, advancements in tissue sampling and imaging play a decisive role in accurate staging and therapeutic decision-making. Fine needle aspiration (FNA), although minimally invasive and widely accessible, is sometimes supplanted or complemented by core needle biopsy (CNB) for superior histopathological characterization and molecular testing accuracy. Furthermore, the incorporation of ^18F-fluorodeoxyglucose positron emission tomography/computed tomography (^18F-FDG PET/CT) provides enhanced resolution for evaluating metabolic tumor activity, facilitating precise staging and enabling the monitoring of therapeutic response dynamics in real time.

Innovations in immunohistochemistry and the integration of liquid biopsy techniques represent a vital leap towards earlier diagnosis and minimally invasive monitoring. The detection of circulating tumor DNA (ctDNA) and other biomolecules in peripheral blood permits longitudinal surveillance of tumor genetic alterations and treatment resistance mechanisms, thereby informing dynamic therapeutic adjustments and personalized patient management strategies without repeated tissue biopsies.

Emerging research is reorienting attention towards mitochondrial metabolism within ATC cells, positing it as a novel therapeutic vulnerability. Tumor cells frequently exhibit altered metabolic phenotypes and dependencies that can be exploited pharmacologically. Targeting mitochondrial pathways involved in energy production and apoptotic regulation may sensitize cancer cells to existing treatments or overcome intrinsic resistance, thus broadening the therapeutic arsenal against ATC.

Simultaneously, cutting-edge modalities involving nanotechnology and oncolytic virotherapy are under rigorous evaluation. Nanoparticles engineered for targeted drug delivery promise enhanced intratumoral concentration of therapeutic agents while minimizing systemic toxicity. Oncolytic viruses, selectively replicating within and destroying cancer cells, additionally stimulate antitumor immune responses and have the potential to modulate radioiodine uptake, a critical limitation in treating thyroid malignancies, thus amplifying radiosensitivity and therapeutic efficacy.

Collectively, these multidisciplinary advances underscore a transformative era for ATC research and clinical care. The amalgamation of molecular genetics, targeted pharmacology, immunotherapy, innovative diagnostics, and novel biologics heralds a comprehensive, precision medicine framework aimed at surmounting the historically poor outcomes associated with ATC. As clinical trials progress and translational insights deepen, the prospect of converting this once uniformly fatal cancer into a manageable chronic disease or even achieving cure is increasingly tangible.

The recent review in Genes & Diseases not only consolidates current knowledge but also inspires a forward-looking ethos prioritizing mechanistic insights and experimental therapeutics at the molecular level. It reflects the journal’s commitment to propelling fundamental and translational research that bridges laboratory discoveries with clinical innovations, nurturing hope for patients confronted with anaplastic thyroid cancer.

Subject of Research: Anaplastic thyroid cancer molecular biology, diagnostic methods, targeted therapy, and immunotherapy.

Article Title: Anaplastic thyroid cancer: Genetic roles, targeted therapy, and immunotherapy

News Publication Date: 2024 (exact date not specified)

References: Zhao Zou, Linhong Zhong, Anaplastic thyroid cancer: Genetic roles, targeted therapy, and immunotherapy, Genes & Diseases, Volume 12, Issue 4, 2025, 101403, DOI: 10.1016/j.gendis.2024.101403

Image Credits: Genes & Diseases

Keywords: Anaplastic thyroid cancer, MAPK pathway, PI3K-AKT-mTOR pathway, BRAF mutation, MEK inhibitors, immunotherapy, PD-L1, fine needle aspiration, core needle biopsy, ^18F-FDG PET/CT, liquid biopsy, mitochondrial metabolism, nanoparticles, oncolytic viruses